Clinical Trials

544 enrolled 29 charts

Lung Neoplasms

NCT05091567 2026-03-10

IMforte

660 enrolled 23 charts 1 FDA

Small Cell Lung Carcinoma

NCT04665856 2026-02-13

SKYSCRAPER-02C

123 enrolled 26 charts

Small Cell Lung Carcinoma

NCT04256421 2026-01-28

SKYSCRAPER-02

490 enrolled 31 charts

Small Cell Lung Carcinoma

NCT03199885 2025-12-30

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

190 enrolled 12 charts

Breast Neoplasms

NCT04148911 2025-12-26

EL1SSAR

184 enrolled 15 charts

Triple Negative Breast Neoplasms

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Prostatic Neoplasms

NCT03755791 2025-12-11

COSMIC-312

837 enrolled 14 charts

Carcinoma, Carcinoma, Hepatocellular, Neoplasms

NCT03735121 2025-12-05

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

438 enrolled 40 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03371017 2025-11-12

IMpassion132

595 enrolled 37 charts

Triple Negative Breast Neoplasms

NCT04487067 2025-09-22

AMETHISTA

152 enrolled 16 charts

Carcinoma, Hepatocellular

NCT04740918 2025-08-08

KATE3

96 enrolled 16 charts

Breast Neoplasms

NCT02908672 2025-07-20

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

514 enrolled 25 charts 2 FDA

Dermatologic

Melanoma

NCT04732286 2025-05-08

A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy

100 enrolled 18 charts

Carcinoma, Hepatocellular

NCT02807636 2025-02-24

IMvigor130

1,213 enrolled 35 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03726879 2024-11-05

IMpassion050

454 enrolled 28 charts

Breast Neoplasms

NCT03191786 2024-10-23

IPSOS

453 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung

NCT03016312 2024-08-09

IMbassador250

759 enrolled 22 charts

Prostatic Neoplasms, Castration-Resistant

NCT04177108 2024-03-27

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

242 enrolled 12 charts

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Skin Diseases, Triple Negative Breast Neoplasms

NCT03125902 2024-03-26

IMpassion131

653 enrolled 33 charts

Triple Negative Breast Neoplasms

NCT02657434 2023-11-21

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

578 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT03197935 2023-10-26

IMpassion031

333 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT03434379 2023-10-23

IMbrave150

558 enrolled 48 charts 2 FDA

Carcinoma, Hepatocellular

NCT03024996 2023-08-03

IMmotion010

778 enrolled 19 charts

Carcinoma, Renal Cell

NCT02763579 2023-07-28

IMpower133

503 enrolled 23 charts 1 FDA

Small Cell Lung Carcinoma

NCT02450331 2023-06-18

IMvigor010

809 enrolled 19 charts

Carcinoma, Transitional Cell

NCT02409342 2023-03-15

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

572 enrolled 32 charts 2 FDA

Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

NCT03038100 2023-02-17

IMagyn050

1,301 enrolled 22 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT02420821 2023-01-30

IMmotion151

915 enrolled 40 charts

Carcinoma, Renal Cell

NCT02425891 2022-07-19

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

902 enrolled 27 charts 1 FDA

Triple Negative Breast Neoplasms

NCT02367794 2022-03-21

A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]

1,021 enrolled 33 charts

Squamous Non-Small Cell Lung Cancer

NCT02367781 2021-08-09

IMpower130

723 enrolled 28 charts 1 FDA

Tumor-Agnostic

Carcinoma

NCT02008227 2019-12-20

OAK

1,225 enrolled 32 charts

Non-Squamous Non-Small Cell Lung Cancer

NCT02788279 2019-12-11

A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)

363 enrolled 19 charts

Colorectal Neoplasms

NCT02302807 2019-08-01

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

931 enrolled 21 charts

Urinary Bladder Neoplasms

NCT02409355 2019-02-15

A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)

8 enrolled 9 charts